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Letters to the Editorto reimplant that vessel separately, but
only if the tear cannot be repaired by
direct suturing reinforced with the
stent-graft device.
Finally, covering the left subclavian
artery was not associated with any
acute malperfusion. Admittedly, the
series is small and left subclavian mal-
perfusion can become an issue during
follow-up. Delayed revascularization
is a simple solution to this problem if
needed. Two patients have developed
type 2 endoleaks and underwent sub-
sequent carotid to subclavian bypass
with embolization at the origin.
If a disease-specific device were
available, it may be easier to preserve
the subclavian artery during this pro-
cedure. More important, approxi-
mately half of the patients presented
with malperfusion, and all were
readily managed in the hybrid oper-
ating room by this technique that opti-
mizes true lumen flow with or without
additional endovascular procedures
performed promptly enough to avoid
permanent end-organ injury.
This procedure is safe and effective,
and we will continue to use commer-
cially available stent-grafts with
modification because we believe this
operation represents an improvement
in care, especially for those patients
with malperfusion. Our hope is that a
new device, specifically designed for
this application, will become avail-
able to allow for more widespread
adoption.
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To the Editor:
I thank Pagano and colleagues1 for
the letter on my comment2 about their
recent article on a mixed-treatment
comparisonmeta-analysis (also known
as ‘‘network meta-analysis’’) of ran-
domized trials comparing aprotinin
and other antifibrinolytics in adult
cardiac surgery.3
I am disappointed with some of the
content in their reply1 because meth-
odologic issues remained unanswered
and unclear. Also, their statements
could potentially contribute to confu-
sion. It is also disturbing if we care-
fully explore their discordant results
with a recent network meta-analysis
of both randomized and observational
evidence by Hutton and colleagues,4
wherein the authors concluded that
‘‘[a]lthough meta-analyses of ran-
domized controlled trials were largely
inconclusive, inclusion of observa-
tional data suggest concerns remain
about the safety of aprotinin. Tranexa-
mic and epsilon-aminocaproic acid
are effective alternatives that may be
safer for patients.’’
I acknowledge randomized trials
are the most rigorous way of deter-
mining whether a causal relation ex-
ists between an outcome and a given
drug. Particularly, randomized trials
have several important features:
random allocation to treatments; pa-
tients and investigators remain un-
aware of which treatment was given
until the trial is terminated; all thera-
peutic interventions are treated identi-
cally except for the experimental
drug; patients are normally analyzed
within the group to which they were
allocated (intention-to-treat analysis);
and the analyses are primary, focused
on estimating the effect size in prede-
fined outcomes. On the same line, it is
generally accepted that meta-analyses
(and more recently, network meta-
analyses) are a useful tool to criticallyof Thoracic and Cardiovascular Surgeassess the totality of clinical evidence
in a research question, but when con-
ducted in a comprehensive and trans-
parent way. It is worthy of note that
even all data in a study-level meta-
analysis came from randomized trials,
the power of randomization is
completely lost (the objects of anal-
ysis are the trials, not the patients),
and the data are reduced to the equiv-
alent of those results derived from
observational data.
It is not, however, true to say that
small-trial bias does not represent an
issue when it comes to comparative
trials; it is widely documented in the
scientific literature whether small
‘‘negative’’ trials could remain unpub-
lished indefinitely, but most impor-
tant, how the potential manipulation
in small trials (eg, selection of specific
patients, selective reporting) could
lead to more favorable effect sizes
compared with those reported in
larger randomized trials.
Finally, I have found some of the
language in the reply1 to be somewhat
unfortunately chosen. Particularly,
they wonder whether my employment
by a governmental public health
agency constitutes a declarable con-
flict of interest; in this sense, I should
declare that the opinions on my
comment2 are completely my own
and do not necessarily represent those
of any regulatory body. I acknowledge
conflicts of interests are common, but
they are a condition not a behavior,
and there is nothing wrong with hav-
ing conflict of interests. No statement
will solve the conflict of interests
problem. It is interesting to show,
however, that although the authors
technically do not breach the Jour-
nal’s formal rules regarding declara-
tion of conflicts of interest, as their
own earlier research indicates, some
of the authors have received honoraria
from aprotinin’s manufacturer.5
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We are grateful to Dr Catalana-
Lopez for his continued comments
regarding our work.
Although we do not want to prolong
unnecessarily this correspondence, a
couple of points are worthy of note
in his response.
First, the suggestion of including
observational evidence in the meta-
analysis is flawed, and we found our-
selves in this position. As Rosenbaum
and Rubin,1 the propensity score
methods used by the authors can
only address confounding when case
mix adjustment is possible to the
extent that the prescriber’s decision
to prescribe a treatment is otherwise
ignorable. This is clearly not the
case in our situation, in which the732 The Journal of Thoracic and Cobservational studies describe a sub-
stantial latency (unmeasurable bias)
associated with the decision to pre-
scribe, which has been incorrectly in-
terpreted as a risk associated with
aprotonin.2,3 Thus, following Dr
Catalana-Lopez’s advice in this
situation would actually compound
the previous errors of interpretation
that have led us to our difficulties
with this agent.
Second, Dr Catalana-Lopez is sim-
ply incorrect when he suggests that
network meta-analyses have the
same status as observational studies.
Network meta-analyses preserve the
original randomization in trials, and
provide fully conditional estimates of
treatment effect. However, network
meta-analyses require an additional
assumption (of exchangeability; ie,
that subjects share characteristics
from the overall population and may,
thus, appear in any of the trials).
Thus, rather than fully giving up the
protection of randomization, we may
consider network meta-analyses to
be quasi-randomized estimates.
Finally, with regard to potential
conflicts of interest, they should be
declared upfront and leave the reader
to decide of their importance. These
authors take conflicts of interest seri-
ously and, as indicated by Dr
Catalana-Lopez, have declared all
possible conflicts in accordance with
required journal requirements.
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CONTRIBUTE TO THE QUASI
PRESERVATION OF
CARDIOPROTECTION BY
REMOTE PRECONDITIONING
WITH ISOFLURANE BUT NOT
PROPOFOL IN CABG
To the Editor:
We read with great interest the
article by Kottenberg and colleagues1
published online in The Journal of
Thoracic and Cardiovascular Surgery
onMarch 1, 2013. They have done a se-
ries of impressive translational works to
explore the underlying mechanisms of
cardioprotection by remote ischemic
preconditioning (RIPC) with isoflurane
or propofol in patients undergoing coro-
nary artery bypass grafting (CABG).1-3
In their fundamental study published in
Acta Anaesthesiologica Scandinavica,2
they designed 2 independent substudies
and found that isoflurane may be
more effective in the preservation of
cardioprotection by RIPC than
propofol. Then, based on 2 conse-
quently separated and independent
studies,2,3 they believed that differen-
tial activation of signal transducer
and activator of transcription 5
(STAT 5) phosphorylation may be the
contributing factor.
Nevertheless, there remains incon-
clusive information about this inter-
esting issue when looking into the
fundamental study. In that study,2 the
male proportion may be even within
the substudy (RIPC vs control with
isoflurane; RIPC vs control with pro-
pofol); however, it may be uneven be-
tween the 2 substudies (isoflurane vs
propofol, 89.7% vs 75.8%; mean dif-
ference, 14%).
Accumulating evidence from ani-
mal studies has supported gender-
specific cardioprotection by ischemic3
